High incidence of posttransplant lymphoproliferative disease in pediatric patients with cystinc fibrosis

American Journal of Respiratory and Critical Care Medicine

Volumn 161, Issue 4 I, 2000, Pages 1252-1255

  Cohen, Alan H ^b   Sweet, Stuart C ^b   Mendeloff, Eric ^b   Mallory Jr , George B ^b   Huddleston, Charles B ^b   Kraus, Madeleine ^b   Kelly, Michael ^b   Hayashi, Robert ^b   DeBaun, Michael R ^a  

^a ST LOUIS CHILDREN S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

LYMPHOCYTE ANTIBODY; THYMOCYTE ANTIBODY;

ADOLESCENT; ARTICLE; CHILD; COHORT ANALYSIS; CYSTIC FIBROSIS; EPSTEIN BARR VIRUS; FEMALE; GRAFT REJECTION; HUMAN; INCIDENCE; INFECTION RISK; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; PEDIATRICS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VIRUS INFECTION;

EID: 0034012157     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.161.4.9901013     Document Type: Article

References (22)

1. Cooper, J., G. Patterson, and E. Trulock. 1994. Results of single and bilateral lung transplantation in 131 consecutive recipients. J. Thorac. Cardiovasc. Surg. 107:460-471.
2. Sweet, S. C., T. L. Spray, C. B. Huddleston, E. Mendeloff, C. E. Canter, D. T. Balzer, N. D. Bridges, A. H. Cohen, and G. B. Mallory, Jr. 1997. Pediatric lung transplantation at St. Louis Children's Hospital 1990-1995. Am. J. Respir. Crit. Care Med. 155:1027-1035.
3. Yousem, S., P. Randhawa, and J. Locker, et al. 1989. Posttransplant lymphoproliferative disorders in heart lung transplant recipients: primary presentation in the allograft. Hum. Pathol. 20:361-369.
4. Aris, R., D. Maia, and I. Neuringer, et al. 1996. Post-transplantation lymphoproliferative disorder in the Epstein-Barr-naive lung transplant recipient. Am. J. Respir. Crit. Care Med. 154:1712-1717.
5. Boyle, G., M. Michaels, and S. Webber, et al. 1997. Posttransplant lymphoproliferative disorders in pediatric thoracic organ recipients. J. Pediatr. 131:309-313.
6. Walker, R., C. Paya, and W. Marshall, et al. 1995. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for post-transplantation lymphoproliferative disorder in adult heart, lung and other solid organ transplantations. J. Heart Lung 14:214-221.
7. Tanner, J., and C. Alfieri. 1996. Interactions involving cycloporin A, interleukin-6, and Epstein-Barr virus lead to the promotion of B-cell lymphoproliferative disease. Leukemia Lymphoma 21:379-390.
8. Cox, K., L. Lawrence-Miyasaki, R. Garcia-Kennedy, et al. 1995. An increased incidence of Epstein-Barr virus and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 59:524-529.
9. Penn, I. 1991. The changing pattern of posttransplant malignancies. Transplant. Proc. 23:1101-1103.
10. Cockfield, S. M., J. Preiksaitis, E. Harvey, C. Jones, D. Hebert, P. Keown, and P. F. Halloran. 1991. Is sequential use of ALG and OKT3 in renal transplants associated with an increased incidence of fulminant posttransplant lymphoproliferative disorder? Transplant. Proc. 23:1106-1107.
11. Newell, K., E. Alonso, and P. Whitington, et al. 1996. Posttransplant lymphproliferative disease in pediatric liver transplantation: interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation 63:370-375.
12. McAlister, V., D. Grant, A. Roy, Z. Yilmaz, C. Ghent, and W. Wall. 1993. Posttransplant lymphoproliferative disorders in liver recipients treated with OKT3 or ALG induction immunosuppression. Transplant. Proc. 25:1400-1401.
13. Swinnen, L., and R. Fisher. 1993. OKT3 monoclonal antibodies induce interleukin-6 and interleukin-10: a possible cause of lymphoproliferative disorders associated with transplantation. Curr. Opin. Nephrol. Hypertens. 2:670-678.
14. Kerem, E., M. Reisman, M. Corey, G. Canny, and H. Levison. 1992. Prediction of mortality in patients with cystic fibrosis. N. Engl. J. Med. 326:1187-1191.
15. Spray, T., G. Mallory, C. Canter, and C. Huddleston. 1994. Pediatric lung transplantation: indications, techniques and early results. J. Thorac. Cardiovasc. Surg. 107:990-1000.
16. Pasque, M., J. Cooper, L. Kaiser, D. Haydock, A. Triantafillou, and E. Trulock. 1990. Improved technique for bilateral lung transplantation: rationale and initial clinical experience. Ann. Thorac. Surg. 49:785-791.
17. Yousem, S. A., G. J. Berry, P. T. Cagle, D. Chamberlain, A. N. Husain, R. H. Hruban, A. Marchevsky, N. P. Ohori, J. Ritter, S. Stewart, and H. D. Tazelaar. 1996. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: lung rejection study group. J. Heart Lung Transplant. 15:1-15.
18. Cooper, J., M. Billington, and T. Egan, et al. 1993. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. J. Heart Lung Transplant. 12:713-716.
19. Harris, N., J. Ferry, and S. Swerdlow. 1997. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin. Diagn. Pathol. 14:8-14.
20. Khan, T., J. Wagener, T. Bost, J. Martinez, F. Accurso, and D. Riches. 1995. Early pulmonary inflammation in infants with cystic fibrosis. Crit. Care Med. 151:1075-1082.
21. Bonfield, T., M. Konstan, P. Burfeind, J. Panuska, and J. M. B. Hilliard. 1995. Normal bronchial epithelial cells constitutively produce the antiinflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis. Am. J. Respir. Cell Mol. Biol. 13:257-261.
22. Tan, K., A. Trull, K. Hue, N. Best, J. Wallwork, and T. W. Higenbottam. 1993. Pharmacokinetics of cyclosporine in heart and lung transplant candidates and recipients with cystic fibrosis and Eisenmenger's syndrome. Clin. Pharmacol. Ther. 53:544-554.